Ponatinib Found to Have Therapeutic Potential for Drug-Resistant KIT mutations in GIST
A recent article in the Clinical Cancer Research Journal discussed a new drug, Ponatinib, that shows therapeutic potential for drug-resistant KIT mutations in GIST.